CurrentCignaPolicy N/A

Enspryng Prior Authorization Policy

Defines Cigna prior authorization requirements, coverage criteria, and conditions not covered for Enspryng (satralizumab) for treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. Applies to Cigna-administered health benefit plans where the policy governs utilization and coverage determinations.

Policy Summary

PayerCigna

PolicyEnspryng Prior Authorization Policy

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateApr 2, 2025

Key ActionObtain prior authorization and document patient is ≥18 and AQP4-IgG positive; approvals are for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18minimum patient age for coverage

1 yearauthorization length

AQP4-IgG+diagnostic requirement

Excludedconcomitant biologics excluded

Coverage Criteria for Enspryng (satralizumab)

FDA-Approved Indication — NMOSD

Covered when ONE of the following is met for the FDA-approved indication of Neuromyelitis Optica Spectrum Disorder:

Overall: Approve for 1 year if either Initial Therapy (A) OR Currently Receiving Enspryng (B) criteria are met.

A) Initial Therapy: Patient is >= 18 years of age; AND diagnosis confirmed by a positive blood serum test for anti-aquaporin-4 (AQP4) antibody; AND the medication is prescribed by or in consultation with a neurologist.

Approve for 1 year.

B) Currently Receiving Enspryng: Patient is >= 18 years of age; AND diagnosis confirmed by a positive blood serum test for anti-aquaporin-4 (AQP4) antibody; AND according to the prescriber the patient has had clinical benefit from the use of Enspryng (examples: reduction in relapse rate, reduction in symptoms such as pain, fatigue, motor function, or slowing in progression); AND the medication is prescribed by or in consultation with a neurologist.

Policy Summary

PayerCigna

PolicyEnspryng Prior Authorization Policy

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateApr 2, 2025

Key ActionObtain prior authorization and document patient is ≥18 and AQP4-IgG positive; approvals are for 1 year when criteria are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior authorization and approval duration

Prior Authorization is required for Enspryng (satralizumab-mwge). Approvals are provided for the duration specified in the policy and Enspryng must be prescribed by or in consultation with a physician who specializes in the condition being treated (typically a neurologist).

Prior authorization required for prescription benefit coverage
Approvals provided for the duration noted in the policy (typically 1 year for initial and continuing therapy)
Prescriber requirement: prescribed by or in consultation with a neurologist or specialist in the condition

Step Therapy

Step therapy / positioning

No step therapy is required. Enspryng is positioned as a first-line treatment option for AQP4-IgG–positive neuromyelitis optica spectrum disorder per guideline recommendations and policy updates.

Step therapy: none required
Placement: first-line treatment option for AQP4-IgG–positive NMOSD

Documentation Required

Required documentation for approval

Document the following for authorization requests: patient age, positive anti-aquaporin-4 (AQP4-IgG) serology, and prescriber attestation of clinical benefit for ongoing therapy. For initial and continuation approvals, confirm the patient is ≥ 18 years old and that diagnosis was confirmed by a positive blood serum test for anti-aquaporin-4 antibody. For continuation, include the prescriber's statement that the patient has experienced clinical benefit (examples: reduced relapse rate, symptom improvement, or slowed progression).

Required documentation: patient is ≥ 18 years of age
Required documentation: positive blood serum test for anti-aquaporin-4 (AQP4-IgG)
Required documentation for continuation: prescriber statement that patient has had clinical benefit from Enspryng (examples: reduction in relapse rate, symptom improvement, slowed progression)
Prescriber specialty: documentation that medication is prescribed by or in consultation with a neurologist

Denial Risk

Concomitant biologic therapy exclusion

Concomitant use of Enspryng with certain biologic therapies is not covered. Requests for combined therapy with these agents should be denied per policy.

Not covered: concomitant use with a rituximab product
Not covered: concomitant use with eculizumab intravenous infusion (Soliris, biosimilars)
Not covered: concomitant use with Ultomiris (ravulizumab-cwyz intravenous infusion)
Not covered: concomitant use with Uplizna (inebilizumab-cdon intravenous infusion)

Definitions

inv-09: Enspryng (satralizumab-mwge) — drug identifier

Generic namesatralizumab-mwge

Brand nameEnspryng

Drug class / mechanismInterleukin-6 (IL-6) receptor antagonist

FDA-approved indication (concise)Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti‑aquaporin‑4 antibody positive

RouteSubcutaneous injection

inv-10: NMOSD — definition of neuromyelitis optica spectrum disorder

Definition (concise)Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune disorder of the brain and spinal cord with optic neuritis and/or myelitis as predominant features

Key clinical consequencesCan cause significant, permanent damage to vision and/or spinal cord function, potentially resulting in blindness or impaired mobility

Typical symptomsOptic neuritis and/or myelitis; may include pain, paralysis, bowel/bladder dysfunction, loss of visual acuity, and uncontrolled motor function

Link to treatment relevancePatients with NMOSD who are anti‑aquaporin‑4 antibody positive are eligible for treatment with Enspryng (satralizumab) per FDA indication

OpenPayer

Enspryng Prior Authorization Policy

Coverage Criteria for Enspryng (satralizumab)

Provider Actions, Authorization & Documentation

Background

Definitions